TG Therapeutics Inc. | Mutual Funds
Mutual Funds that own TG Therapeutics Inc.
SPDR S&P Biotech ETF
2,804,049
3.39%
7,215
0.61%
09/06/2018
Fidelity Select Biotechnology Portfolio
2,723,437
3.29%
0
0.38%
07/31/2018
Vanguard Total Stock Market Index Fund
1,471,915
1.78%
0
0%
07/31/2018
iShares Russell 2000 ETF
1,238,346
1.5%
-660
0.03%
09/06/2018
Franklin Small Cap Growth Fund
875,000
1.06%
0
0.37%
03/31/2018
UBS (Lux) Equity Fund - Biotech
874,771
1.06%
0
0.9%
01/31/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
827,200
1%
-92,900
0.45%
06/30/2018
Vanguard Extended Market Index Fund
806,305
0.97%
23,300
0.01%
07/31/2018
Fidelity Advisor Biotechnology Fund
727,046
0.88%
-115,950
0.32%
07/31/2018
Candriam Equities L - Biotechnology
598,000
0.72%
213,000
0.56%
07/31/2018
| Address |
2 Gansevoort Street
New York New York 10014
United States
|
|
Employees
|
- |
| Website |
http://www.tgtherapeutics.com |
| Updated |
07/08/2019 |
| TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. |
